Author(s): Zhen C; Wang L; Feng Y; Whiteway M; Hang S; Yu J; Lu H; Jiang Y;

Candidiasis, which presents a substantial risk to human well-being, is frequently treated with azoles. However, drug-drug interactions caused by azoles inhibiting the human CYP3A4 enzyme, together with increasing resistance of Candida species to azoles, represent serious issues with this class of drug, making it imperative to develop innovative antifungal ...

Article GUID: 38995235

Author(s): He S; Singh D; Helfield B;

Localized and reversible plasma membrane disruption is a promising technique employed for the targeted deposition of exogenous therapeutic compounds for the treatment of disease. Indeed, the plasma membrane represents a significant barrier to successful delivery, and various physical methods using light, sound, and electrical energy have been developed to ...

Article GUID: 35456718

Author(s): Godoy P; Darlington PJ; Whiteway M;

Candida albicans, an important fungal pathogen of humans, displays different morphologies, such as yeast, pseudo-hyphae and hyphae, which are recognized unequally by phagocytic cells of the innate immune response. Once C. albicans cells invade host tissues, immune cells such as macrophages are attracted to the site of infection and activated to recognize, ...

Article GUID: 35450285

Author(s): Brunetti SC, Arseneault MKM, Gulick PJ

BMC Genomics. 2018 Dec 11;19(1):898 Authors: Brunetti SC, Arseneault MKM, Gulick PJ

Article GUID: 30537926